Company intelligence / Profile preview

invIOs

Ownership: Private
Employees: ~35
Development stage: Phase 1

Overview

invIOs has demonstrated strong preclinical proof-of-concept data with its lead programs. The small molecule candidate INV501 shows robust anti-tumoral immune responses and can cross the blood-brain barrier. The EPiC platform’s first asset, APN401, has shown initial clinical results as an ambulatory autologous transient cell therapy targeting Cbl-b. Clinical trials are ongoing/planned for advanced solid tumors and glioblastoma.

Therapeutic areas: Oncology
Modalities: Small molecules (e.g., INV501)Cell therapies (autologous, e.g., APN401, INV441, INV451)CAR-T cell approaches (INV451)
Industry: Biotech

Drug pipeline

7 assets

APN401

6 more assets in the full pipeline.

Partnerships

Dana-Farber Cancer Institute/Harvard Medical School collaboration on glioblastoma programsMedical University of Innsbruck partnership on lung cancer/CAR-T program.

Beyond the preview

Go deeper on invIOs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on invIOs.